Perioperative glycemic control by insulin glargine in type 2 diabetic patients.
- Author:
Nai-Shi LI
1
;
Wen-Hui LI
;
Heng WANG
Author Information
- Publication Type:Journal Article
- MeSH: Blood Glucose; analysis; Diabetes Mellitus, Type 2; blood; drug therapy; Humans; Hypoglycemic Agents; adverse effects; therapeutic use; Insulin; adverse effects; analogs & derivatives; therapeutic use; Insulin Glargine; Insulin, Long-Acting; Perioperative Care; Retrospective Studies
- From: Acta Academiae Medicinae Sinicae 2008;30(1):109-111
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the feasibility of perioperative glycemic control with insulin glargine in type 2 diabetic patients.
METHODSWe retrospectively analyzed the clinical data of 16 type 2 diabetic inpatients treated with insulin glargine (research group) and 16 type 2 diabetic inpatients treated with the traditional intensified insulin therapy (control group) for perioperative glycemic control.
RESULTSThe fasting blood glucose values of the diabetic patients in the research group on the day of surgery and the first 3 postoperative days were (7.5 +/- 1.8), (8.2 +/- 1.8), (7.6 +/- 1.6), and (7.2 +/- 1.1) mmol/L, respectively, and were (9.0 +/- 2.8), (10.4 +/- 2.4), (8.8 +/- 2.7), (9.0 +/- 2.0) mmol/L in the control group, respectively. The fasting blood glucose values in the research group were significantly lower than the control group on the first and third postoperative day (P = 0.02 and 0.01, respectively). No hypoglycemic events were observed and all wounds were healed well in both groups.
CONCLUSIONWith satisfied fasting blood glucose level and fewer episode of hypoglycemia, perioperative glycemic control by insulin glargine in type 2 diabetic patients is safe, effective, and convenient.
